The Surprising Science Between Height and Longevity

The speaker notes that this practice was part of his routine even when eating higher protein, suggesting that the fasting effect overshadowed protein's potential to raise IGF-1. He uses it in conjunction with other strategies (caloric moderation, leanness, exercise) to keep IGF-1 at around 100 ng/mL. He does not specify the exact daily fasting duration, but time-restricted eating typically involves 14–18 hours of fasting.

The speaker reports staying around 10% body fat year-round without compromising muscle mass or bone density. He achieves this through caloric moderation (2,000–2,500 kcal/day) and exercise. He believes this is a key lever in keeping his IGF-1 low despite adequate protein intake.

The speaker notes that despite his moderate intake, his IGF-1 has remained low, and that even a past high-protein period (200 g) did not elevate it, attributing this to his overall metabolic health and fasting practice. He recommends this intake as part of a multi-factor approach.

The speaker credits exercise as a key reason he maintains optimal blood sugar levels and insulin sensitivity. He does not specify the type or duration, but the context implies a mix of resistance and aerobic training to build and maintain muscle mass while keeping metabolism efficient.

The speaker has monitored his IGF-1 for 8 years, observing values between 78 and 100 ng/mL. He uses these data to argue that his approach keeps IGF-1 in a range he considers optimal for longevity, especially cancer risk reduction. He acknowledges that observational data would place him in a higher-risk category, but he reconciles this with centenarian data and his robust muscle and bone health.

The speaker presents a meta-analysis (2023) that identified 120–160 ng/mL as the IGF-1 range with lowest all-cause and cancer mortality. However, he notes that centenarians have a mean IGF-1 of only 64 ng/mL, though he acknowledges survivorship bias (IGF-1 declines with age). He contends that low IGF-1 below 100 ng/mL is associated with higher mortality mainly because it reflects frailty, sarcopenia, and malnutrition—states he avoids. He also addresses the potential risk of neurodegeneration: studies show that IGF-1 below 110 ng/mL is not associated with increased Alzheimer's risk compared to 120–170 ng/mL, but very low levels <100 ng/mL might still raise dementia risk, though data are unclear. His conclusion: an IGF-1 of ~100 ng/mL is optimal for minimizing cancer risk while preserving muscle and bone health, thus achieving longevity. This is a shift from the standard U-curve interpretation, arguing that the lower end becomes dangerous only when accompanied by protein/energy deficiency or poor body composition.

The speaker describes a Spanish study from 1835–1869 showing that men over 170 cm lived 7.6 years longer than men under 160 cm. However, in those born between 1900–1939, the difference disappeared because living standards and medical care became more equitable. A 2002 study on baseball players, who share similar access to healthcare and finances, found that the shortest players (162 cm) lived longer than the tallest (193 cm) throughout the 20th century. A US veterans study further showed that men under 175.3 cm lived 4.95 years longer than taller men, and those under 170.2 cm lived 7.46 years longer than those over 182.9 cm. Weight also mattered: men under 63.6 kg lived 7.72 years longer than those over 90.9 kg. He concludes that within modern societies, being shorter and lighter is associated with increased longevity, likely due to lower lifetime exposure to growth hormone and IGF-1.

The speaker explains that evolution doesn't care about maximum lifespan; it cares only about passing genes on. Therefore, traits that benefit reproduction and survival during youth can be selected even if they cause harm later. Growth hormone and IGF-1 are prime examples: they drive bone and muscle growth during development, increasing reproductive potential, but later in life elevate cancer risk and mortality. He cites a UK Biobank study of 276,000 individuals showing that higher polygenic scores for reproductive traits were associated with lower survivorship to age 76, while those with low scores were most likely to live past 76. This directly demonstrates antagonistic pleiotropy in humans. He also notes that the relationship holds across species: smaller individuals within a species live longer than larger ones (e.g., small dogs live twice as long as large dogs), consistent with the idea that growth-promoting mechanisms shorten lifespan.

He details each factor: (1) Time-restricted eating and intermittent fasting increase time in a fasted state, which lowers IGF-1. (2) Keeping body fat around 10% year-round prevents excess adiposity from raising insulin and IGF-1. (3) He limits calories to about 2,000–2,500 per day and does not overeat. (4) He consumes moderate protein (1.6 g/kg, ~130 g), noting that his IGF-1 remained around 100 ng/mL even when he ate 200 g of protein, suggesting that other factors like fasting and insulin sensitivity are more dominant. (5) Exercise maintains optimal blood sugar and insulin sensitivity, preventing high blood sugar from raising IGF-1. He also acknowledges that genetics likely play a role, as his IGF-1 has always been around 100. This combination, he argues, can keep IGF-1 in a range that minimizes cancer risk without causing frailty, provided muscle mass and bone density are consciously maintained.